|Day Low/High||49.97 / 50.00|
|52 Wk Low/High||31.03 / 50.67|
Lance, Teva Pharmaceuticals, NCI, Emergency Medical Services and Knight Capital are 'buy'-rated stocks.
Lance, Pegasystems, Monro Muffler, Rollins and Check Point Software are 'buy'-rated mid-cap stocks.
Lance, Teva Pharmaceuticals, NCI, Bio-Reference Labs and Knight Capital are 'buy' rated stocks.
Lance, Pegasystems, Monro Muffler Brake, Rollins and Check Point Software are 'buy'-rated mid-cap stocks.
Lance and Teva are among fast-growth stocks that receive 'buy' recommendations from TheStreet.com.
Small caps like Marvel, Cott and Ebix have risen more than 35% in the past three months, but those big gains are unlikely to continue.
TheStreet.com rates Lance, Pegasystems, Monro Muffler, Rollins and Ralcorp "buy."
Lance, Rollins and Pegasystems are among mid-cap companies with 'buy' recommendations from TheStreet.com Ratings.
Teva Pharmaceutical Industries and Pegasystems are among companies with 'buy' ratings from TheStreet.com.
Ralcorp is benefiting from demand for cheap food and its acquisition of Post Cereals.
Knight Capital and Lance are two top companies with 'buy' ratings from TheStreet.com.
Snack company Lance offers a strong financial position and products that will remain in demand regardless of the economy.
J&J Snack Foods is benefiting as Americans munch their way through the recession.
Lance reported a better-than-expected first-quarter profit, buoyed by higher selling prices and the acquisition of Archway Cookies.
Earnings roundup: Ford posts better-than-expected $1.4B loss, Schlumberger earnings drop
Outlook roundup: ITT cuts profit, sales forecasts; American Electric Power backs year outlook
Lance boosts 2009 profit guidance based on expectations for higher sales
Lance 1st-quarter profit jumps on Archway Cookies acquisition, higher selling prices
Steve Bernard, founder of Cape Cod Potato Chips brand, dies of cancer at Mass. hospital
Herman Miller upgraded; Inergy, Textron and American Tower downgraded.
The business software maker slumped on smaller profits.
BioCryst continues its upward trajectory after the FDA grants fast-track approval to its bird flu drug.
The Canadian cola giant hires a finance chief away from the maker of Toast Chee and Nip Chee.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.